Involvement of endocrine system in a patient affected by Glycogen storage disease 1b: speculation on the role of autoimmunity

Daniela Melis*, Roberto Della Casa, Francesca Balivo, Giorgia Minopoli, Alessandro Rossi, Mariacarolina Salerno, Generoso Andria and Giancarlo Parenti

Abstract
Glycogen storage disease type 1b (GSD1b) is an inherited metabolic defect of glycogenolysis and gluconeogenesis due to mutations of the SLC37A4 gene and to defective transport of glucose-6-phosphate. The clinical presentation of GSD1b is characterized by hepatomegaly, failure to thrive, fasting hypoglycemia, and dyslipidemia. Patients affected by GSD1b also show neutropenia and/or neutrophil dysfunction that cause increased susceptibility to recurrent bacterial infections. GSD1b patients are also at risk for inflammatory bowel disease. Occasional reports suggesting an increased risk of autoimmune disorders in GSD1b patients, have been published. These complications affect the clinical outcome of the patients. Here we describe the occurrence of autoimmune endocrine disorders including thyroiditis and growth hormone deficiency, in a patient affected by GSD1b. This case further supports the association between GSD1b and autoimmune diseases.

Keywords: Glycogen storage disease 1b, Autoimmunity, Thyroiditis, Growth hormone deficiency, Inflammatory bowel disease

Background
Glycogen storage disease type 1b (GSD1b; OMIM 232220) is an inherited metabolic defect due to mutations of the SLC37A4 gene that encodes a microsomal glucose-6-phosphate transporter (G6PT) [1]. Decreased transport of glucose-6-phosphate (G6P) across the microsomal membrane causes inability of G6P to come in contact with the catalytic unit of glucose-6-phosphatase (G6Pase-alpha), insufficient conversion of G6P into glucose and phosphate, and defective glycogenolysis and gluconeogenesis [2,3]. The biochemical defect of GSD1b results in a phenotype characterized by hepatomegaly and failure to thrive, which is similar to that of other liver glycogenoses, and in typical biochemical abnormalities (fasting hypoglycemia, hyperlactic acidemia, hyperlipidemia, hyperuricemia). The treatment of GSD1b is mainly based on a dietary regimen with frequent meals, nocturnal gastric drip feeding and use of uncooked starches with low glycemic index.

In addition to the classical phenotype of glycogenoses, GSD1b is associated with neutropenia and/or neutrophil dysfunction that cause increased susceptibility to recurrent bacterial infections, aphthous stomatitis, and inflammatory bowel disease (IBD) [4,5]. Although these manifestations are highly debilitating and impact significantly on patients’ quality of life, their pathophysiology is still poorly characterized. Granulocyte-Colony Stimulating factor (G-CSF) is commonly used, in addition to the standard dietary treatment, for the management of neutrophil abnormalities in GSD1b patients and is effective in decreasing the frequency of infections [1,4-7]. These abnormalities of neutrophil count and function have been claimed to be a predisposing factor to autoimmune diseases [8,9]. Reports have been published in the recent literature on the association between GSD1b and IBD [4], autoimmune thyroiditis [10], growth hormone (GH) deficiency [11], and autoimmune myasthenia gravis [12]. The possible role of autoimmunity in GH deficiency has also been reported [13].

* Correspondence: daniela.melis@unina.it
Department of Translational Medical Sciences, Section of Pediatrics, Federico II University, Via S. Pansini 5, 80131 Naples, Italy
Here we describe a patient affected by GSD1b that showed several manifestations of autoimmunity including IBD, autoimmune thyroiditis and autoimmune GH deficiency.

**Case presentation**

GDN, a male, was the first child of third cousin parents. He was delivered by caesarean section. In the neonatal period he presented with hypoglycemia, seizures, hyperbilirubinemia (16 mg/dL), and hemolytic disease due to AB0 incompatibility.

At the age of three months he was first referred to Genetic Clinic Unit because of fasting hypoglycemia with seizures, liver enlargement, recurrent infections, and candidiasis. The diagnosis of GSD1b was based on the clinical presentation, on the typical biochemical profile with lactic acidosis, dyslipidemia, and hyperuricemia, and on the assay of glucose-6-phosphatase in fresh and frozen liver samples. When the molecular diagnosis of the disease became available, the diagnosis was confirmed by the mutational analysis of the SLC37A4 gene, showing homozygosity for the mutation c.1211-1212delCT.

A diet based on frequent meals and nocturnal gastric drip-feeding was started and the patient was included in a follow-up program at our Department. Biochemical and growth parameters improved after the start of dietary treatment.

During the follow-up, however, GDN presented with many of the known complications of GSD1b.

At the age of 6 months neutropenia was detected. The median neutrophil count, over a 5-year follow-up period, was 1160/mm$^3$, ranging between 230 and 4523. A therapy with G-CSF was started at the age of 6 months with a dose of 3–5 μg/kg/day.

Recurrent respiratory and gastro-intestinal infections and splenomegaly were also recorded.

When he was 8 years old, glomerular hyperfiltration and microalbuminuria were detected on routine biochemical evaluations and treatment with ACE-inhibitors was started to prevent further progression of renal disease.

In addition to the known complications of GSD1b, the patient presented with disorders suggesting autoimmune involvement.

At the age of 7 years, given the presence of stomatitis aphthosa and perianal ulcers, an ileocolonoscopy was performed showing signs of non-specific chronic inflammation. A scintigraphy with 99mTc-Technetium-labeled autologous white cell (Tc-WCS) showed moderate to high degree neutrophil chemiotaxis at the ileocecal junction. A terminal ileum ultrasonography showed increased bowel wall thickness. The treatment of the intestinal involvement was based on the use of an elemental diet and periodic administration of antibiotics.

Biochemical evidence of autoimmune thyroiditis with subclinical hypothyroidism was observed at the age of 12 years. The diagnosis was based on repeated increased basal TSH levels and thyroid auto-antibodies (Table 1), with abnormal echogenicity of the parenchyma on a thyroid ultrasound scan. During the follow-up, TSH levels were always below 10 μU/ml and thus he never started a replacement therapy with L-thyroxine [14,15]. At that time, a complete panel of serum autoantibodies was assayed showing increased antibodies against ANA, Anti-C1Q, Anti-C3d (Table 1).

When he was 14-years-old, reduced height velocity (Figure 1), short stature, and retarded bone maturation (corresponding to 12 years) were observed. At that time pubertal stage was G2P2, TSH was 5.6 μU/ml with normal fT4 1.2 ng/dl (normal values 0.7-1.7). A GH-RH plus arginine test was performed, showing reduced GH response (peak 7.8 ng/dl) (Figure 2). High titer of anti-pituitary antibodies recognizing growth hormone-producing cells (>1:8) were also detected, indicating an autoimmune growth hormone deficiency. A pituitary Magnetic Resonance Imaging was normal, showing a normal gland architecture. The adrenal gland function was also evaluated, showing normal basal hormone levels and normal response to a dynamic low dose ACTH test (Table 1).

At the age of 16 years he also showed delayed pubertal development; also in this case no treatment was started. At that time, considering the increased number of infections and their seriousness and the appearance of skin pigmentation, adrenal function was re-evaluated, showing basal ACTH 15 ng/ml and basal cortisol 54 ng/ml. A dynamic low dose ACTH test was also performed showing a significant increase in cortisol levels (cortisol T0 51.1 ng/ml, T30 221 ng/ml, T60 229 ng/ml, T90 260 ng/ml), thus suggesting a normal functioning of the adrenal gland and only a slight pituitary dysfunction.

**Conclusions**

We report on a patient presenting with different manifestations related to altered immune response, such as increased susceptibility to bacterial infections, autoimmune thyroiditis and autoimmune GH deficiency. In GSD1b, neutopenia and impaired neutrophil function represent the *primum movens* of the reduced response to infection.

The occurrence of autoimmune disorders has been reported in GSD1b only in the recent years and little is known about its pathophysiology. Different hypotheses may be considered to explain the presence of autoimmune disorders in GSD1b patients.

Firstly it is known that autoimmunity may be related to the defective function of neutrophils. In fact, there are several disorders in which abnormal function of neutrophil is associated with autoimmunity. For example carrier mothers of children with chronic granulomatous disease, an X-linked defect of phagocytosis, often develop...
discoid lupus [8]. Similarly, combined cellular and antibody deficiencies, such as Wiskott-Aldrich syndrome, are associated with an increased risk for juvenile rheumatoid arthritis and autoimmune hemolytic anemia [9].

Secondly, immunologic defects may determine a failure to exclude microbial antigens, thus resulting in chronic immunologic activation, with the rising of autoimmune manifestations [16]. In GSD1b patients, recurrent infections may lead to increased expression of MHC antigens or trigger the immune response through molecular mimicry and cross-reactivity between endogenous and microbial peptides.

In addition, it might be hypothesized that, in GSD1b patients, failure of neutrophils to achieve intracellular killing of bacteria may result in induction of lymphocyte T_{H1}-type proliferation as a compensatory mechanism [16].

In our patient we observed only minor endocrine autoimmune manifestations, involving pituitary gland, thyroid and adrenal gland. Considering that TSH levels were always below 10 μU/ml and basal ACTH and cortisol were in the low reference range, he never started a specific therapy. As far as GH deficiency is concerned no replacement therapy was started, considering that rhGH is known to stimulate gluconeogenesis and to increase fasting insulin levels and insulin-resistance [17,18] thus interfering with glucose metabolism and possibly worsening metabolic imbalance in GSD1. In addition it is known the promoting effect of GH on the growth of liver cell adenomas [19], a known long-term complication in GSD1. Therefore, we decided to monitor auxological parameters before beginning therapy with rhGH, considering its potential dangerousness.

Although no hormone replacement therapy was started in our patient, it is difficult to predict whether in other patients these manifestations may contribute to the clinical picture of the diseases and impact on patients’ quality of life. It has been recently reported that patients with GSD1b are more likely to experience a poor quality of life [20].

Table 1 Endocrine profile at 14 years

| Thyroid             | Results | Reference values |
|---------------------|---------|------------------|
| TSH (μU/ml)         | 5.6     | 0.5–4.5          |
| FT3 (pg/ml)         | 3.5     | 1.6–3.4          |
| FT4 (ng/dl)         | 1.2     | 0.7–1.7          |
| Anti-TPO (UI/ml)    | 57      | 0–40             |
| Anti-thyroglobulin (UI/ml) | 121 | 0–40 |
| Growth hormone & pituitary | | |
| Basal GH (ug/l)     | 0.04    | 0.2–5            |
| IGF-I (ug/l)        | 53.9    | 100–500          |
| Anti-pituitary antibodies | 1.8 | 0 |
| Adrenals            | | |
| Basal ACTH (ng/ml)  | 17.6    | 10–130           |
| Basal cortisol (ng/ml) | 120 | 50–200 |
| ACTH test           | | |
| Cortisol (ng/ml)    | | |
| T0                  | 120     | 50–200           |
| T30                 | 236     | >100             |
| T60                 | 249     | >100             |
| T90                 | 260     | >100             |
| Anti-adrenal gland antibodies | Absent | Absent |
| Anti-ACTH antibodies | Absent | Absent |
| Auto-antibody profile | | |
| ANA (U/ml)          | 3.1     | 0–1              |
| Ds-DNA (U/ml)       | 0       | 0–5              |
| ANCA (U/ml)         | 0       | 0–5              |
| ASCA (U/ml)         | 0       | <20              |
| Cardiolipin (PLU/ml) | 0     | <10              |
| Phospholipid (U/ml) | 0       | <10              |
| Acetylcholine receptor (nmol/l) | 0 | 0–0.25 |
| Anti-C1Q (U/ml)     | 140     | 1–40             |
| Anti-C3d (U/ml)     | 120     | 0–24             |
Figure 1 Patient’s growth pattern. Height velocity deceleration was observed when the patient was 15 years old. The arrow indicates the time GH-RH plus arginine dynamic test was performed. Final height was below mid-parental height.

Figure 2 Graphic representation of GH-RH plus arginine dynamic test demonstrating GH deficiency in the patient. The patient is represented by ▲.
In conclusion, given the known association between immunodeficiency and autoimmunity, we suggest monitoring GSD1b patients for autoimmune disorders.

Consent
Written informed consent was obtained from the mother of the patient for the publication of this Case report. A copy of the written consent is available for being reviewed by the Editor-in-Chief of this journal.

Abbreviations
GSD1b: Glycogen storage disease type 1b; G6P: Glucose-6-phosphate; G6Pase: Glucose-6-phosphatase; IBD: Inflammatory bowel disease; G-CSF: Granulocyte-Colony Stimulating factor; GH: Growth Hormone; Tc-WCS: Scintigraphy with 111In-Technetium-labeled autologous white cell.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DM, RDC, FB, AR, GM, MCS followed up the patient over the 15-year follow-up, GP and GA were the consultant metabolic doctors, DM and GP wrote the paper. All authors read and approved the final manuscript.

Received: 9 September 2013 Accepted: 27 February 2014
Published: 19 March 2014

References
1. Chen YT: Glycogen storage disease. In: The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Edited by Scriver CR, Beaudet AL, Valle D, Sly WS, Kinzler K. New York: McGraw-Hill; 2001:1521–1551.
2. Lee KJ, Shelly LL, Lin B, Sidbury JB, Chen YT, Nordlie RC: mutations in the glucose-6-phosphatase gene in patients with glycogen storage disease type 1a and 1aSP but not 1b and 1c. J Clin Invest 1995, 95:234–240.
3. Galli L, Ormico A, Marcolongo P, Fulceri R, Burchell A, Melis D, Paolini R, Gatti R, Lam C-W, Benedetti A, Sorrentino V: Mutations in the glucose-6-phosphate transporter (G6PT) gene in patients with glycogen storage disease type 1b and 1c. FEBS Lett 1999, 459:255–258.
4. Melis D, Parenti G, Villa R, Digges M, Violi F, Berini Canani R, Della Casa R, Zammarchi E, Andria G, Benedetti A, Gatti R, Lam C-W, Benedetti A, Sorrentino V: Mutations in the glucose-6-phosphatase gene in patients with glycogen storage disease type 1b and 1c. FEBS Lett 1999, 499:255–258.
5. Melis D, Parenti G, Della Casa R, Romano A, Turco S, Benedetti A, Sorrentino V: Mutations in the glucose-6-phosphate transporter (G6PT) gene in patients with glycogen storage disease type 1a and 1aSP but not 1b and 1c. J Clin Invest 1995, 95:234–240.
6. Melis D, Parenti G, Della Casa R, Romano A, Turco S, Benedetti A, Sorrentino V: Mutations in the glucose-6-phosphatase gene in patients with glycogen storage disease type 1b and 1c. FEBS Lett 1999, 459:255–258.
7. Visser G, Rake JP, Labrune P, Leonard JV, Moses S, Ullrich K, Wendel U, Smit GP: Consensus guidelines for management of glycogen storage disease type 1b – European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 2002, 161(Suppl 1):S121–S123.
8. Kaplan M: Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 2011, 7:691–699.
9. Catucci M, Castello MC, Pala F, Bosticardo M, Villa A: Autoimmunity in Wiskott-Aldrich syndrome: an unsolved enigma. Front Immunol 2012, 3:209.
10. Melis D, Pivonello R, Parenti G, Della Casa R, Salerno M, Lombardi G, Sebastio G, Colao A, Andria G: Increased prevalence of thyroid autoimmunity and hypothyroidism in patients with glycogen storage disease type 1a. J Pediatr 2007, 150:300–305.
11. Melis D, Pivonello R, Parenti G, Della Casa R, Salerno M, Balivo F, Piccolo P, Di Somma C, Colao A, Andria G: The growth hormone-insulin-like growth factor axis in glycogen storage disease type 1: evidence of different growth patterns and insulin-like growth factor levels in patients with glycogen storage disease type 1a and 1b. J Pediatr 2010, 156:653–670.
12. Melis D, Balivo F, Della Casa R, Romano A, Taurisano R, Capaldo B, Riccardi G, Monsurro MR, Parenti G, Andria G: Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders? J Inherit Metab Dis 2008, 31(Suppl 2):S227–S231.
13. De Bellis A, Colao A, Tirelli G, Rucco G, Di Somma C, Battaglia M, Pane E, Bellastella G, Dello Iacovo A, Sinisi AA, Bizzarro A, Bellastella A: Autoimmunity as a possible cause of growth hormone deficiency. J Endocrinol Invest 2008, 31:1132–1134.
14. Radetti G, Maselli M, Buzi F, Corrias A, Musa A, Cambiaso P, Salemo M, Cappa M, Bairocci M, Gattard R, Mineva A, Loche S: The natural history of the normal/mild elevated TSH serum levels in children and adolescents with Hashimoto’s thyroiditis and isolated hyperthyrotropinemia: a 3-year follow-up. Clin Endocrinol (Oxf) 2012, 76:394–398.
15. Wasniewska M, Salemo M, Cassio A, Corrias A, Aversa T, Zollini G, Capalbo D, Bai M, Musa A, De Luca F: Prospective evaluation of the natural course of idiopathic subclinical hypothyroidism in childhood and adolescence. Eur J Endocrinol 2009, 160:417–421.
16. Selesman JW: The association between immunodeficiency and the development of autoimmune disease. Adv Dent Res 1996, 10:57–61.
17. Giovelli C, Rotteti S, Ronchi CL, Cappellini V, Ferrante E, Onsi E, Arosio M, Beck-Peccoz P: Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 2004, 53:740–743.
18. Moller N, Jørgensen JO, Abildgård N, Orskov L, Schmitz O, Christiansen JS: Effects of growth hormone on glucose metabolism. Horm Res 1991, 36(Suppl 1):32–35.
19. Espat J, Chamberlain RS, Sklar C, Blumgart LH: Hepatic adenoma associated with recombinant human growth hormone therapy in a patient with Turner’s syndrome. Dig Surg 2000, 17:640–643.
20. Sechi A, Deroma L, Paci S, Lapolla A, Carubbi F, Burlina A, Rigoldi M, Di Rocco M: Quality of life in adult patients with glycogen storage disease type I: results of a multicenter Italian study. JIMD Rep 2013 (Epub ahead of print).

doi:10.1186/1824-7288-40-30
Cite this article as: Melis et al.: Involvement of endocrine system in a patient affected by Glycogen storage disease 1b: speculation on the role of autoimmunity. Italian Journal of Pediatrics 2014 40:30.